News | December 27, 2012

Biotronik Announces First U.S. Implants of its Bare Metal Stent

Company moves forward with IDE trial to enter U.S. market

December 27, 2012 — Biotronik announced that the first implant has taken place in the BIOHELIX-I trial in the United States. The BIOHELIX–I trial is set to evaluate the safety and performance of the Pro-Kinetic Energy coronary bare metal stent. The first implant was successfully performed by H. Barrett Cheek of Carolina Cardiology Cornerstone at High Point Regional Hospital in High Point, N.C.

The BIOHELIX-I trial is a prospective, nonrandomized, multicenter, investigational device exemption (IDE) study that will utilize Biotronik’s Pro-Kinetic Energy coronary stent system in patients with symptomatic, ischemic heart disease. More than 300 patients will be enrolled in the study, which is registered on

Saurabh Gupta, M.D., director of the cardiac catheterization laboratory at Oregon Health & Science University in Portland, Ore., is the national principal investigator of the BIOHELIX-I study. “The thin cobalt chromium struts of the Pro-Kinetic Energy allow for greater flexibility and a reduced crossing profile, which translates into a highly deliverable stent,” Gupta said.

He added, “The clinical safety and performance of the Pro-Kinetic Energy stent has been demonstrated in recent results of the ENERGY registry, presented at the TCT 2012 conference. The BIOHELIX-I study will provide additional insight and experience into the clinical application of the Pro-Kinetic Energy stent for patients with ischemic heart disease.”

The Pro-Kinetic Energy is a thin strut (60?m/0.0024 inches) cobalt chromium, bare metal stent, completely sealed with a thin layer of amorphous silicon carbide called PROBIO. This passive coating is designed to reduce the amount of ions released from the stent, potentially reducing adverse reactions post-implantation.

The ENERGY registry was an all-comers registry of more than 1,000 patients with a complex population of 39 percent B2/C lesions and 46 percent acute coronary syndrome patients. At 12 months, Pro-Kinetic Energy showed a low 8.8 percent rate of major adverse cardiac events (MACE), including a 3.4 percent rate of target lesion revascularization (TLR). A subgroup analysis showed similarly low 12-month MACE rates in acute coronary syndrome (ACS) patients, elderly patients, and patients with small vessels or diabetes.

“Biotronik is very pleased to offer this state-of-the-art coronary stent technology to U.S. patients enrolled in the BIOHELIX study,” said Mark Johnson, program director for Biotronik’s U.S. vascular intervention business. “The Pro-Kinetic Energy provides both patients and clinicians with an optimal choice for their coronary vascular therapy needs.”

For more information:

Related Content

New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
Overlay Init